Among these studies, eight included patients with all molecular subtypes [22,23,24,25,26,27,28,29], one included only patients with triple negative BC (TNBC) [31] and the last one included only patients with hormone receptor-positive/HER2-negative BC [30]. This evidence concerns the gene NR4A1 and breast cancer.